BIO 2014: Post-Myriad patent rejections 'incredibly case-specific'

26-06-2014

BIO 2014: Post-Myriad patent rejections 'incredibly case-specific'

Lightspring / Shutterstock.com

Patent rejections based on 35 USC §101, which relate to patent eligibility, are “incredibly case-specific”, making it difficult to identify trends or draw broad conclusions, said Matthew McFarlane, a partner at Robins, Kaplan, Miller & Ciresi LLP at the BIO International Convention yesterday (Wednesday).


BIO 2014; Myriad; Prometheus; Bloomberg BNA; patent eligibility.

LSIPR